Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan's Takeda Reportedly Offering $12B For Europe's Nycomed

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal, if confirmed, would boost Takeda's European and emerging markets presence, providing an additional €3.2 billion in revenues to help offset forthcoming patent expiries.

You may also be interested in...



As Takeda Integrates Its Nycomed Acquisition, Europe Bears Brunt Of Job Cuts

Takeda is to close two R&D facilities in Germany and to cut commercial activities in the U.S., as it looks for cost savings from the 2011 acquisition of Nycomed.

Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives

Takeda Pharmaceuticals Co. Ltd.'s €9.6 billion ($13.6 billion) purchase of privately held Nycomed AS, confirmed May 19 after a week of speculation, satisfies a number of strategic and financial imperatives for Japan's largest drug maker, as it faces generic competition to best-selling diabetes drug Actos (pioglitazone) from 2012 and seeks to expand its footprint beyond Japan and the U.S.

Takeda Gains Access To European OTC Market With $13.7B Nycomed Buy

Japanese pharma giant Takeda Pharmaceuticals Co. Ltd. gains access to the European OTC market with its $13.7 billion purchase of Swiss firm Nycomed AS.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel